PD-1/PD-L1抑制剂在晚期肝细胞肝癌治疗中的研究进展

晚期原发性肝细胞肝癌(hepatocellular carcinoma,HCC)的系统治疗主要包括靶向治疗、化疗以及免疫治疗。近3年,程序性死亡受体-1(programmed death receptor-1,PD-1)/程序性死亡受体-1配体(programmed death receptor-1 ligand,PD-L1)抑制剂在晚期HCC治疗中取得突破性进展。纳武单抗(nivolumab)和帕博利珠单抗(pembrolizumab)先后被美国食品药品管理局(FDA)批准用于HCC二线治疗。多个PD-1/PD-L1抑制剂联合系统治疗的Ⅰ、Ⅱ期临床研究初步显示出较好的疗效和安全性。阿特珠单抗(atezolizumab)联合贝伐单抗一线治疗成为首个在Ⅲ期临床研究中证实优于现有标准治疗索拉非尼的全新疗法。本文就近年PD-1/PD-L1抑制剂在晚期HCC治疗中的研究进展进行概述。

Research progress in the use of PD-1/PD-L1 inhibitors for advanced hepatocellular carcinoma

Systemic treatment of advanced hepatocellular carcinoma (HCC) includes targeted therapy, chemotherapy, and immunotherapy. In recent years, the treatment of advanced HCC has progressed with the use of programmed death receptor-1(PD-1)/programmed death receptor-1 ligand (PD-L1) inhibitors. Nivolumab and pembrolizumab have been approved by the US Food and Drug Administration (FDA) as a second-line treatment for advanced HCC. Multiple phase I/II clinical studies of PD-1/PD-L1 inhibitors combined with other systemic treatments have revealed good efficacy and safety. In a phase III clinical study, atezolizumab plus bevacizumab, as a new first-line treatment strategy, has been shown to be superior to the existing standard treatment (sorafenib). Here, we review the current research and progress in the use of PD-1/PD-L1 inhibitors for advanced HCC.